Amicus Therapeutics Inc
NASDAQ:FOLD

Watchlist Manager
Amicus Therapeutics Inc Logo
Amicus Therapeutics Inc
NASDAQ:FOLD
Watchlist
Price: 9.325 USD 1.25%
Market Cap: 2.8B USD

Amicus Therapeutics Inc
Investor Relations

In the ever-evolving landscape of biotech, Amicus Therapeutics Inc. stands as a beacon of innovation, rooted deeply in the realm of rare and orphan diseases. Founded with the mission to harness advanced therapies for conditions with limited treatment options, the company has carved a niche in developing treatments that hinge on cutting-edge science. Specifically, Amicus focuses on creating next-generation therapies involving chaperone proteins and genetic medicines. These specialized therapies work by stabilizing and enhancing the function of faulty proteins that are hallmarks of many genetic disorders, thereby directly addressing the underlying causes of these conditions. Their portfolio, prominently featuring Galafold (migalastat) for Fabry disease, exemplifies their approach—leveraging precision medicine to cater to patients who have been underserved by traditional pharmaceutical models.

Revenue generation for Amicus Therapeutics predominantly revolves around the commercialization of Galafold, which is approved in numerous global markets. Galafold offers a personalized approach, being targeted towards individuals with Fabry disease who possess amenable genetic mutations. This specificity not only underscores Amicus's commitment to precision therapeutics but also reinforces its competitive edge, as the treatment reduces the necessity for enzymatic replacement, a conventional route with broader systemic impacts. Beyond its current offerings, Amicus is strategically investing in its pipeline of gene therapies, aiming to provide breakthroughs in conditions like Pompe disease and other rare metabolic disorders. By enhancing existing therapies and fostering new breakthroughs, Amicus not only upholds its commitment to patient-centric solutions but also bolsters its financial sustainability through strategic innovation and market expansion.

Show more
Loading

Earnings Calls

2024 Q3
Nov 6, 2024
Show Transcript
Previous
Next
Amicus Therapeutics Reports Strong Q3 Growth and Raises Revenue Guidance
2024 Q3
Nov 6, 2024

Amicus Therapeutics achieved a remarkable $142 million in Q3 revenue, a 37% surge year-over-year, driven by Galafold's $120 million sales, up 19%. The company raised its full-year revenue growth forecast to 30-32%, reflecting strong demand in treating Fabry disease, with Galafold's annual growth now projected at 16-18%. The launch of Pombiliti and Opfolda for Pompe disease is also robust, with expected sales between $69-71 million. Non-GAAP profitability is confirmed for the year, alongside effective expense management. Overall, the foundation for ongoing growth appears solid as patient identification improves, particularly in underserved markets.

Show Full Analysis

Management

Mr. Bradley L. Campbell M.B.A.
CEO, President & Director
No Bio Available
Mr. Simon Nicolas Reade Harford
Chief Financial Officer
No Bio Available
Ms. Ellen S. Rosenberg J.D.
Chief Legal Officer & Corporate Secretary
No Bio Available
Mr. David M. Clark
Chief People Officer
No Bio Available
Dr. Jeffrey P. Castelli Ph.D.
Chief Development Officer
No Bio Available
Ms. Samantha Prout
Chief Accounting Officer & Controller
No Bio Available
Dr. Jill Weimer Ph.D.
Chief Science Officer
No Bio Available
Mr. Andrew Faughnan
Senior Director of Investor Relations
No Bio Available
Mr. Patrik S. Florencio Esq.
Global Chief Compliance & Risk Officer
No Bio Available
Ms. Diana Moore
Head of Global Corporate Communications
No Bio Available

Contacts

Address
PENNSYLVANIA
PHILADELPHIA
3675 Market Street
Contacts
+12159217600.0
www.amicusrx.com